NEW YORK – AI diagnostics firm Tempus said on Tuesday that it has inked a deal with Roche's Flatiron Health that will allow healthcare providers to order Tempus' genomic cancer tests through Flatiron's electronic medical record system.
Chicago-based Tempus said that the deal will provide access to its testing menu for about 4,200 healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform and its Molecular Profiling Integration technology.
Financial and other terms of the deal were not disclosed.
"By leveraging Flatiron's Molecular Profiling Integration within OncoEMR, we are enabling oncologists to access our comprehensive genomic tests with greater efficiency and precision, ultimately enhancing patient care and outcomes," Tempus Chief Medical Officer Ezra Cohen said in a statement.
Stephen Speicher, senior medical director for Flatiron, added that the collaboration will help its customers to provide more personalized cancer care and improve patient outcomes.
As part of the deal, providers will have access to Tempus' tests such as the xT solid tumor and normal match DNA sequencing test, xR whole-transcriptome sequencing RNA test, liquid biopsy-based xF/xF+ tests, xG/xG+ hereditary cancer germline tests powered by Ambry Genetics, and xM/xM (NeXT Personal Dx) minimal residual disease and monitoring tests. They also will have access to AI-enabled, algorithmic, add-on tests from Tempus.
Tempus went public earlier this year with a $410.7 million initial public offering and announced last week that it had entered into a $600 million agreement to acquire Ambry Genetics.
Meanwhile, Flatiron and Myriad Genetics said last month that they had formed a collaboration to make Myriad's MyRisk hereditary cancer test available to order through OncoEMR. Caris Life Sciences and Guardant Health have in previous years inked deals to make their tests available through the platform.